Spartanburg Medical Research | Spartanburg, SC
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This study will look at how a new medicine called NNC0519-0130 helps people with excess body weight lose weight. The study will test up to 6 different doses of NNC0519-0130. Participants will take 1-2 injections once a week. The study medicine will be injected under skin with a thin needle in the stomach, thigh, or upper arm. The study will last for about 42 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Female of non-childbearing potential, or male.
a. For US only: Female of childbearing potential using highly effective non-systemic methods of contraception with low user-dependency at least 2 months prior to screening and willingness to continue using it through-out the study, or male.
Age 18-75 years (both inclusive) at the time of signing the informed consent.
History of at least one self-reported unsuccessful dietary effort to lose body weight.
a) BMI ≥ 27.0 kg/m2 with the presence of at least one weight-related co-morbidity including, but not limited to, hypertension, dyslipidaemia, obstructive sleep apnoea or cardiovascular disease.
b) BMI ≥ 30.0 kg/m2.
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
355 participants in 13 patient groups, including a placebo group
Loading...
Central trial contact
Novo Nordisk
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal